Fatty acid hydroxylase-associated neurodegeneration (FAHN) is a rare disease that exhibits brain modifications and motor dysfunctions in early childhood. The condition is caused by a homozygous or compound heterozygous mutation in (), whose encoded protein synthesizes 2-hydroxysphingolipids and 2-hydroxyglycosphingolipids and is therefore involved in sphingolipid metabolism. A few FAHN model organisms have already been established and give the first insight into symptomatic effects. However, they fail to establish the underlying cellular mechanism of FAHN so far. is an excellent model for many neurodegenerative disorders; hence, here, we have characterized and validated the first FAHN model. The investigation of loss of dfa2h lines revealed behavioral abnormalities, including motor impairment and flying disability, in addition to a shortened lifespan. Furthermore, alterations in mitochondrial dynamics, and autophagy were identified. Analyses of patient-derived fibroblasts, and rescue experiments with human FA2H, indicated that these defects are evolutionarily conserved. We thus present a FAHN model organism that provides new insights into the cellular mechanism of FAHN.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794614 | PMC |
http://dx.doi.org/10.3389/fcell.2022.1000553 | DOI Listing |
Dev Med Child Neurol
December 2024
Innovative Therapies in Pediatric Neurology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
Aim: To investigate the natural progression of SGCE-associated myoclonus dystonia from symptom onset in childhood to early adulthood.
Method: Myoclonus and dystonia were monitored using rating scales in two cohorts of participants from Spain and the Netherlands. Individual annualized rates of change were calculated and longitudinal trends were assessed using Bayesian mixed models.
Mov Disord Clin Pract
December 2024
Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Background: Imbalance is the most commonly reported side effect following focused ultrasound (FUS) thalamotomy for essential tremor (ET). It remains unknown which patients are more likely to develop imbalance following FUS treatment.
Objective: To identify preoperative and treatment-related sonication parameters that are predictive of imbalance following FUS treatment.
Neurol Clin Pract
October 2024
The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA.
Background And Objectives: Disease-modifying treatments (DMTs) such as gene therapy are currently under investigation as a potential treatment for Huntington disease (HD). Our objective was to estimate the long-term natural history of HD progression and explore the potential efficacy impacts and value of a hypothetical DMT using a decision-analytic modeling framework.
Methods: We developed a health state transition model that separately analyzed 40-year-old individuals with prefunctional decline (PFD, HD Integrated Staging System [HD-ISS] stage <3, total functional score [TFC] 13), active functional decline Shoulson and Fahn category 1 (SF1, HD-ISS stage 3, TFC 13-11), and SF2 (HD-ISS stage 3, TFC 10-7).
Med
August 2024
Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; School of Medicine and Life Sciences, Far Eastern Federal University, Vladivostok 690090, Russia. Electronic address:
Background: De novo pathogenic variants in GNAO1-the gene encoding the major neuronal G protein Gαo-cause pediatric encephalopathies and other neurological deficiencies largely refractory to available therapies. Zn emerged to restore guanosine triphosphate hydrolysis and cellular interactions of pathogenic Gαo; dietary zinc salt supplementation improves lifespan and motoric function in a Drosophila disease model.
Methods: Using biochemical, animal, and first-in-human studies, we provide support for the patient stratification and application of zinc acetate in GNAO1-associated disorders.
Mov Disord Clin Pract
August 2024
Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
Background: Clinically assisted nutrition and hydration via percutaneous endoscopic gastrostomy (PEG) is a therapeutic option to ameliorate the difficulties associated with enhanced catabolism, weight loss, and dysphagia in Huntington's disease (HD).
Objectives: The objective is to provide insights into demographics, staging (Shoulson-Fahn), complications, weight trajectories, and survival rates in people with HD (pwHD) who underwent PEG.
Methods: This retrospective study included 705 consecutive pwHD who attended our HD clinic between July 2006 and March 2024, of whom 52 underwent PEG.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!